Figure 5
From: A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma
Treatment with anti-IL4Rα-NPs induces sustained control of lung inflammation. (a) Lung sections of OVA-sensitized mice treated with anti-IgG1-NPs, free anti-IL4Rα and anti-IL4Rα-NPs. The sections were isolated 24 h following the last instillation. The upper panels are stained with H&E, the middle panels show Periodic acid Schiff staining (for mucus hypersecretion) and the lower panels show immunohistochemical staining with an anti-PEG antibody to show the tissue distribution of the NPs. (b) Histological assessment of lung sections obtained 7 days following the last instillation with either free anti-IL4Rα or anti-IL4Rα-NPs. The upper panels are stained with H&E, and the lower panels show periodic acid-Schiff staining. In contrast to treatment with free anti-IL4Rα, where lung inflammation and obstruction of the bronchiole lumen through mucus accumulation resumed 7 days following the last instillation, lungs treated with anti-IL4Rα-NPs maintained a low level of inflammation and mucus clearance. Scale bar, 100 μm.
